Current Research: Pediatric Hematology-Oncology

CCG4941L --National Wilms Tumor Late Effects Study

Although most people in this study enjoy good health, some may be at risk for certain health conditions. We are collecting information from as many participants as possible in order to determine if they or their offspring are at risk for adverse medical conditions. If there is more than one case of Wilms tumor in a given family, we plan to work with geneticists to try to estimate heritability and recurrence risks.

Eligibility

Patients may be eligible for this trial if:

• Were registered as a Studied or Followed patient on NWTS-5;
• Were <16 years of age at the time of diagnosis of a stage I-V favorable histology Wilms tumor, stage I-V focal or diffuse, anaplastic Wilms tumor, stage I-V clear cell sarcoma of the kidney (CCSK) or stage I - V rhabdoid tumor of the kidney (RTK), including those tumors with any of the above histologies which occurred in fused (horseshoe or discoid) kidneys, or a solitary kidney, or at an extra-renal site;
• Survived for two years after diagnosis.

Trial Sponsor

• Emory University

Project Begin Date

• Jun 2005

Tentative Project End Date

• Ongoing

Back to Pediatric Hematology-Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .